Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
In recent years, the number of patients with ocular diseases is increasing as a consequence of population aging. Among them, one of the most common is the age-related macular degeneration (AMD), a condition that leads to vision loss if it is not treated. AMD is a multifactorial disorder with two advanced forms, dry and neovascular AMD. Currently, although there is no approved therapy that significantly impacts dry AMD progression, several pharmacologic therapies exist for neovascular AMD. Notwithstanding, evidence suggests a suboptimal result in a high number of patients receiving these therapeutic options. Consequently, finding effective strategies is not only a still unmet medical need in dry AMD but also in neovascular AMD. This underlines the need for new drug delivery technologies that can improve the pharmacological action and drug concentration at the target sites. In this regard, sustained drug delivery systems are presented as the most promising therapeutic options in AMD patients. This review summarized the pathogenesis and the current treatment options for AMD, focusing on the emerging ocular sustained drug delivery approaches undergoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AMD is one of the leading causes of irreversible visual impairment in individuals 50 years or older.4,5”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“VEGF is a key mediator of the pathological angiogenesis and the formation of macular choroidal neovascularisation (CNV) that, without intervention, is directly responsible for vision loss in nAMD.2,4,5,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Neovascular AMD (nAMD) is an advanced form of AMD, accounting for 10–20% of AMD cases and is responsible for 80–90% of severe visual loss in this disorder.5,6”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Age-related macular degeneration (AMD) is a disease of the retina that can progress to vision impair and even blindness in the elderly [1].”
BackgroundEffects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638 · cited 1×
“Nevertheless, AREDS supplementation is not recommended in smoker patients due to beta-carotene increasing the risk of lung cancer [33].”
BackgroundAge-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093 · cited 1×
“Dry AMD accounts for 80–90% of cases, whereas neovascular AMD is responsible for 10–20% of AMD cases, the latter explaining the 90% of severe vision loss related to this disease [5,6].”
BackgroundLaVail, M. M., Unoki, K., Yasumura, D., Matthes, M. T., Yancopoulos, G. D., & Steinberg, R. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11249 · Cited by 719
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561 · cited 1×
“GA presents as a gradual degeneration of retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris that leads to progressive central vision loss [7,8].”
BackgroundProtection of mouse photoreceptors by survival factors in retinal degenerations.
LaVail, M. M., Yasumura, D., Matthes, M. T., Lau-Villacorta, C., Unoki, K., Sung, C. –., & Steinberg, R. H. (1998) · PubMed · Cited by 537
Pennington, K. L., & DeAngelis, M. M. (2016) · Eye and Vision · doi:10.1186/s40662-016-0063-5 · Cited by 480
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Campochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.167 · Cited by 343
Zhang, K., Hopkins, J. J., Heier, J. S., Birch, D. G., Halperin, L. S., Albini, T. A., Brown, D. M., Jaffe, G. J., Tao, W., & Williams, G. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018987108 · Cited by 310 · cited 1×
“A pilot, proof of concept, phase II trial has already shown promising results for encapsulated cell-based CNTF in GA [50,51].”
BackgroundThe Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Campochiaro, P. A., Marcus, D. M., Awh, C. C., Regillo, C., Adamis, A. P., Bantseev, V., Chiang, Y., Ehrlich, J. S., Erickson, S., Hanley, W. D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.036 · Cited by 272
SENILE MACULAR DEGENERATION: REVIEW OF EPIDEMIOLOGIC FEATURES
FERRIS, F. L. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113624 · Cited by 269 · cited 1×
“Dry AMD accounts for 80–90% of cases, whereas neovascular AMD is responsible for 10–20% of AMD cases, the latter explaining the 90% of severe vision loss related to this disease [5,6].”
BackgroundLong-Term Effects of Vitamins C and E, β-Carotene, and Zinc on Age-related Macular Degeneration
Chew, E. Y., Clemons, T. E., Agrón, E., Sperduto, R. D., SanGiovanni, J. P., Kurinij, N., & Davis, M. D. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.021 · Cited by 268
Permeability of Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and Lipophilicity
Pitka¨nen, L., Ranta, V.-P., Moilanen, H., & Urtti, A. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1051 · Cited by 261
Stahl, N., & Yancopoulos, G. D. (1994) · Journal of Neurobiology · doi:10.1002/neu.480251111 · Cited by 246 · cited 1×
“Its biological activities are mediated through a heterotrimeric complex formed by CNTF receptor alpha (CNTFRα), glycoprotein 130 (gp130), and leukemia inhibitory factor (LIF) receptor beta, as well as downstream signal transduction pathways [48].”
BackgroundHeier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229 · cited 1×
“In another phase I clinical trial [68], intravitreal administration of AAV2 coding soluble VEGF receptor (sFLT01) was shown to be safe and well tolerated over 1 year follow-up.”
BackgroundEye: anatomy, physiology and barriers to drug delivery
Cholkar, K., Dasari, S. R., Pal, D., & Mitra, A. K. (2013) · Elsevier eBooks · doi:10.1533/9781908818317.1 · Cited by 228
Cayouette, M., & Gravel, C. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.4-423 · Cited by 219
Recent developments in the treatment of age-related macular degeneration
Holz, F. G., Schmitz-Valckenberg, S., & Fleckenstein, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71029 · Cited by 206
Kauper, K., McGovern, C., Sherman, S., Heatherton, P., Rapoza, R., Stabila, P., Dean, B., Lee, A., Borges, S., Bouchard, B., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9970 · Cited by 192 · cited 1×
“A pilot, proof of concept, phase II trial has already shown promising results for encapsulated cell-based CNTF in GA [50,51].”
BackgroundRakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189 · cited 1×
“In phase I [63,65], patients (n = 8) were randomly assigned (3:1) to receive a single subretinal injection of either low- and high-dose rAAV.”
MethodHolekamp, N. M., Campochiaro, P. A., Chang, M. A., Miller, D., Pieramici, D., Adamis, A. P., Brittain, C., Evans, E., Kaufman, D., Maass, K. F., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2021.09.016 · Cited by 189 · cited 1×
“In the Archway clinical trial [57], a total of 248 patients with recently diagnosed neovascular AMD received treatment with the PDS and 167 with monthly ranibizumab injections.”
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186 · cited 1×
“A Phase I clinical trial tested the safety and expression profile of a lentiviral Equine Infectious Anemia Virus (EIAV) vector-encoding endostatin/angiostatin (Retino-Stat®) [69].”
Method(2003) · Ophthalmology · doi:10.1016/j.ophtha.2003.08.020 · Cited by 177
GASS, J. D. M., AGARWAL, A., LAVINA, A. M., & TAWANSY, K. A. (2003) · RETINA · doi:10.1097/00006982-200312000-00001 · Cited by 174
Agrón, E., Mares, J., Clemons, T. E., Swaroop, A., Chew, E. Y., & Keenan, T. D. L. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.018 · Cited by 169
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 167
Constable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152 · cited 1×
“In the phase IIa study [64], the safety and tolerability of the highest dose rAAV.”
BackgroundAdvances in ocular drug delivery: emphasis on the posterior segment
Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.935338 · Cited by 142 · cited 1×
“Within the literature, different studies showed that the intravitreal and periocular routes are the preferred routes for drug delivery [24].”
BackgroundLim, J. H., Wickremasinghe, S. S., Xie, J., Chauhan, D. S., Baird, P. N., Robman, L. D., Hageman, G., & Guymer, R. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.09.013 · Cited by 141
Peden, M. C., Suñer, I. J., Hammer, M. E., & Grizzard, W. S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.018 · Cited by 131 · cited 1×
“Nevertheless, despite the documented benefits of anti-VEGF agents, evidence suggests a suboptimal result in a high number of neovascular AMD patients receiving this treatment [42].”
BackgroundMaurice, D. M., & Polgar, J. (1977) · Experimental Eye Research · doi:10.1016/0014-4835(77)90136-1 · Cited by 127 · cited 1×
“Drug permeability through the sclera mainly depends on molecular radius and surface charge [19].”
BackgroundSlakter, J. S., Bochow, T. W., D’Amico, D. J., Marks, B. B., Jerdan, J. A., & Sullivan, E. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.019 · Cited by 116 · cited 1×
“An additional phase III clinical trial compared 1 year safety and efficacy of anecortave acetate 15 mg suspension to PTD with veteportin in patients with predominantly classic subfoveal CNV secondary to AMD [77].”
BackgroundPermeability of ocular vessels and transport across the blood-retinal-barrier
Törnquist, P., Alm, A., & Bill, A. (1990) · Eye · doi:10.1038/eye.1990.41 · Cited by 115 · cited 1×
“As RPE, BRB represents a barrier for large molecules and different studies reported that molecular weight can determine the possibility to pass through tight junctions between the endothelial cells, so macromolecules are restricted to retinal space [22].”
BackgroundApplication of encapsulated cell technology for retinal degenerative diseases
Tao, W. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.7.717 · Cited by 109 · cited 1×
“To overcome this challenge, encapsulated cell technology (ECT), particularly the NT-501 implant, was developed to provide a sustained drug delivery system right into the vitreous cavity [49].”
BackgroundNEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes
Pauleikhoff, D. (2005) · Retina · doi:10.1097/00006982-200512000-00016 · Cited by 108
Cheruvu, N. P. S., & Kompella, U. B. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0404 · Cited by 103
The Anecortave Acetate Clinical Study Group (2003) · RETINA · doi:10.1097/00006982-200302000-00003 · Cited by 96
Pharmacokinetics of Intraocular Drug Delivery by Periocular Injections Using Ocular Fluorophotometry
Ghate, D., Brooks, W., McCarey, B. E., & Edelhauser, H. F. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0954 · Cited by 93 · cited 1×
“Among the periocular pathways, the posterior juxtascleral, subconjunctival, suprachoroidal, and trans-scleral routes are the mainly used in sustained drug delivery systems to the posterior segment of the eye (Figure 1) [27].”
BackgroundHadziahmetovic, M., & Malek, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.612812 · Cited by 90 · cited 1×
“Age is the main non-modifiable risk factor, whereas smoking is the major modifiable risk factor associated with this pathology [4].”
BackgroundGrassmann, F., Fleckenstein, M., Chew, E. Y., Strunz, T., Schmitz-Valckenberg, S., Göbel, A. P., Klein, M. L., Ratnapriya, R., Swaroop, A., Holz, F. G., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126636 · Cited by 88
Maloney, M. H., Payne, S. R., Herrin, J. S., Sangaralingham, L. R., Shah, N. D., & Barkmeier, A. J. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.062 · Cited by 88 · cited 1×
“Although the intravitreal route can allow access for delivering drugs next to the target tissue, certain risks are present such as retinal detachment or endophthalmitis [25].”
BackgroundRezar-Dreindl, S., Sacu, S., Eibenberger, K., Pollreisz, A., Bühl, W., Georgopoulos, M., Krall, C., Weigert, G., & Schmidt-Erfurth, U. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19772 · Cited by 76 · cited 1×
“In addition, this clinical trial investigated the course of inflammatory and angiogenic cytokines in the aqueous humor of neovascular AMD patients in both study arms and healthy age-matched controls undergoing cataract surgery [81].”
BackgroundConstable, I. J., Lai, C.-M., Magno, A. L., French, M. A., Barone, S. B., Schwartz, S. D., Blumenkranz, M. S., Degli-Esposti, M. A., & Rakoczy, E. P. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.018 · Cited by 76 · cited 1×
“month 12 primary endpoint, participants were additionally followed for two more years, with protocol-specified visits at 18 and 36 months [66].”
MethodKhanani, A. M., Callanan, D., Dreyer, R., Chen, S., Howard, J. G., Hopkins, J. J., Lin, C.-Y., Lorenz-Candlin, M., Makadia, S., Patel, S., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.11.004 · Cited by 76 · cited 2×
“5 mg injections in 220 patients with documented response to anti-VEGF agents [54,56].”
BackgroundKuppermann, B. D., Patel, S. S., Boyer, D. S., Augustin, A. J., Freeman, W. R., Kerr, K. J., Guo, Q., Schneider, S., López, F. J., & on behalf of the Brimo DDS Gen 1 Study Group (2020) · Retina · doi:10.1097/iae.0000000000002789 · Cited by 72 · cited 1×
“A phase IIa clinical trial evaluated the safety and efficacy of Brimo DDS Generation 1 (132 μg and 264 μg brimonidine) in patients with GA from AMD [43].”
MethodRakoczy, E. P., Magno, A. L., Lai, C.-M., Pierce, C. M., Degli-Esposti, M. A., Blumenkranz, M. S., & Constable, I. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.03.006 · Cited by 70
Arias, L., Armadá, F., Donate, J., García-Arumí, J., Giralt, J., Pazos, B., Piñero, A., Martínez, F., Mondéjar, J. J., Ortega, I., et al. (2009) · Eye · doi:10.1038/sj.eye.6703053 · Cited by 67
Vavvas, D. G., Small, K. W., Awh, C. C., Zanke, B. W., Tibshirani, R. J., & Kustra, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718059115 · Cited by 67
Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules
Crowell, S. R., Wang, K., Famili, A., Shatz-Binder, W., Loyet, K. M., Chang, V., Liu, Y., Prabhu, S., Kamath, A. V., & Kelley, R. F. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.6.1 · Cited by 64 · cited 1×
“Due to its high composition in water, similar viscosity and diffusion coefficients in the vitreous humor are expected, restricting positively charged molecules [23].”
BackgroundRauch, R., Weingessel, B., Maca, S. M., & Vécsei‐Marlovits, P. V. (2011) · Retina · doi:10.1097/iae.0b013e3182018df6 · Cited by 62
Review of neovascular age-related macular degeneration treatment options.
Holekamp, N. M. (2019) · PubMed · Cited by 62
AL-3789: a novel ophthalmic angiostatic steroid
Clark, A. F. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.12.1867 · Cited by 55 · cited 1×
“Anecortave acetate is a synthetic angiostatic agent that inhibits blood vessel growth by suppressing the proteases required for vascular endothelial cell migration and does not exhibit glucocorticoid receptor-mediated biological activities [72].”
BackgroundSeddon, J. M., Silver, R. E., & Rosner, B. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308624 · Cited by 55 · cited 1×
“Notwithstanding, it has been noted that a percentage of patients display an augmented risk of progression while on supplementation, probably due to their genetic background [35,36].”
BackgroundPrevalence of age-related macular degeneration in Spain
Spanish Eyes Epidemiological (SEE) Study Group (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.187773 · Cited by 55
Posterior Drug Delivery Via Periocular route: Challenges and Opportunities
Waite, D., Wang, Y., Jones, D., Stitt, A., & Raj Singh, T. R. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0097 · Cited by 54 · cited 1×
“As compared with intravitreal delivery, this method is more effective for delivery to the external area of posterior eye but, in contrast, it is less efficient at reaching the retina [26].”
MethodTuuminen, R., Uusitalo‐Järvinen, H., Aaltonen, V., Hautala, N. M., Kaipiainen, S., Laitamäki, N., Ollila, M., Rantanen, J., Välimäki, S., Sipilä, R., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13501 · Cited by 50
Age‐Related Macular Degeneration: A Practical Approach to a Challenging Disease
Bourla, D. H., & Young, T. A. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00771.x · Cited by 45
Kuppermann, B. D., Goldstein, M., Maturi, R. K., Pollack, A., Singer, M. A., Tufail, A., Weinberger, D., Li, X., Liu, C.-C., Lou, J., et al. (2015) · Ophthalmologica · doi:10.1159/000381865 · Cited by 40 · cited 1×
“The clinical trial conducted by Allergan [79] randomized and treated a total of 243 patients with DEX implant or sham procedure (1:1), who received two protocol-mandated intravitreal ranibizumab injections.”
MethodSchmidt-Erfurth, U. M., Michels, S., Michels, R., & Aue, A. (2005) · European Journal of Ophthalmology · doi:10.1177/112067210501500411 · Cited by 35 · cited 3×
“No clinically relevant serious treatment-related safety issues associated with either the study medication or the procedure for administration were identified by the Independent Safety Committee [75,76].”
BackgroundOzurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study)
Chaudhary, V., Barbosa, J., Lam, W., Mak, M. S. B., Mavrikakis, E., & Mohaghegh, M. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2016.04.020 · Cited by 34 · cited 1×
“On the other hand, the OARA study randomized a total of 10 patients to receive DEX intravitreal implants in combination with ranibizumab or ranibizumab monotherapy after a 3 month ranibizumab loading period [82].”
BackgroundPerspectives of Stem Cell-Based Therapy for Age-Related Retinal Degenerative Diseases
Holáň, V., Heřmánková, B., & Kössl, J. (2017) · Cell Transplantation · doi:10.1177/0963689717721227 · Cited by 33 · cited 2×
“To date, there are no approved therapies that significantly impact the progression of GA [7,28,29], although the use of Age-Related Eye Disease Study (AREDS) supplementation has been shown to diminish AMD progression [30,31].”
BackgroundEpidemiología de la degeneración macular asociada con la edad. Situación en España
Damián, J., Pastor‐Barriuso, R., Armadá, F., & Arias, L. (2006) · Atención Primaria · doi:10.1157/13090016 · Cited by 32
Augustin, A. J., D’Amico, D. J., Mieler, W. F., Schneebaum, C., & Beasley, C. H. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-0961-4 · Cited by 29 · cited 2×
“No clinically relevant serious treatment-related safety issues associated with either the study medication or the procedure for administration were identified by the Independent Safety Committee [75,76].”
BackgroundRezar‐Dreindl, S., Eibenberger, K., Buehl, W., Georgopoulos, M., Weigert, G., Krall, C., Dunavoelgyi, R., Schmidt-Erfurth, U. M., & Sacu, S. (2016) · Retina · doi:10.1097/iae.0000000000001264 · Cited by 23 · cited 1×
“[80] showed that the total number of ranibizumab reinjections and the time until first ranibizumab retreatment were reduced in the patient groups treated with a combination of intravitreal DEX implant and ranibizumab (n = 20) as compared with the group receiving intravitreal ranibizumab monotherapy (n = 20) during 12…”
ResultLim, J. I., Niec, M., & Wong, V. G. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306002 · Cited by 20 · cited 1×
“A phase I study was designed to evaluate the safety and evidence of efficacy of the combination of IBI-20089 plus monthly pro re nata (PRN, “as needed”, monthly injections only in case of active disease) ranibizumab in neovascular AMD patients [78].”
BackgroundGene Therapy for Age-Related Macular Degeneration
Constable, I. J., Blumenkranz, M. S., Schwartz, S. D., Barone, S., Lai, C.-M., & Rakoczy, E. P. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000222 · Cited by 19 · cited 1×
“In phase I [63,65], patients (n = 8) were randomly assigned (3:1) to receive a single subretinal injection of either low- and high-dose rAAV.”
Method
Research works printed but not linked: 1
- Damian, 2006, Epidemiology of age-related macular degeneration. Situation in Spain, Aten. Primaria, 38, 51
Cited by
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
“2,4,5,7 Repeated intravitreal bolus injections of VEGF inhibitors (anti-VEGF) can inhibit CNV growth and leakage and stabilise or improve vision outcomes in patients with nAMD.”
BackgroundA comprehensive review of artificial intelligence models for screening major retinal diseases
Hassan, B., Raja, H., Hassan, T., Akram, M. U., Raja, H., Abd-Alrazaq, A. A., Yousefi, S., & Werghi, N. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10736-z · Cited by 49
Latifi‐Navid, H., Behrooz, A. B., Jamehdor, S., Davari, M., Latifinavid, M., Zolfaghari, N., Piroozmand, S., Taghizadeh, S., Bourbour, M., Shemshaki, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111555 · Cited by 18
Ghosh, A. K., Nikumbh, U. S., Shukla, C. K., Laul, R. S., Dixit, A., Mahapatra, S. K., Nayak, S., Shah, U. M., Parwal, S., Narendran, V., et al. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00883-5 · Cited by 9
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7
Metadata
- Authors
- Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., & González-Andrades, M.
- Affiliations
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-15
- Volume
- 14
- Issue
- 7
- Pages
- 1473
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9319243
- OpenAlex
- W4285733205
- Cited by
- 19
- References
- 71
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 3
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, PAIDI2020)
- Consejería de Salud y Familias, Junta de Andalucía, co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
- Plan Andaluz de Investigación, Desarrollo e Innovación (ERDF/ESF, PAIDI2020)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
- Consejería de Salud y Familias, Junta de Andalucía (ERDF/ESF, PAIDI2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- age-related macular degeneration, sustained drug release, dry age-related macular degeneration, neovascular AMD, ocular drug delivery, anti-VEGF therapy, AMD pathogenesis, clinical trials, vision loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.